Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ping Mao

Showing results (541-550 of 565) with videos related to

Pageof 57
Sort By:
European Journal of Cancer (Oxford, England : 1990)|February 26, 2017
Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomised controlled trialLei Chen, Chao-Su Hu, Xiao-Zhong Chen, et al.
Cell Reports. Medicine|February 12, 2025
Advanced image-identified extranodal extension of retropharyngeal lymph nodes in the refinement of N classification for nasopharyngeal carcinomaWei Jiang, Gao-Yuan Wang, Guan-Jie Qin, et al.
Journal of Hematology & Oncology|October 18, 2022
Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemiaYa-Fang Ma, Ying Lu, Qian Wu, et al.
Molecular Cancer|January 12, 2021
Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responsesYu-Pei Chen, Jia-Wei Lv, Yan-Ping Mao, et al.
BMJ (Clinical Research Ed.)|February 6, 2023
Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trialYan-Ping Mao, Shun-Xin Wang, Tian-Sheng Gao, et al.
Journal of the National Cancer Institute|October 23, 2020
A Gene-Expression Predictor for Efficacy of Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal CarcinomaYuan Lei, Ying-Qin Li, Wei Jiang, et al.
Plos One|October 15, 2015
Impact of Chemotherapy Delay on Overall Survival for AML with IDH1/2 Mutations: A Study in Adult Chinese PatientsJing-Han Wang, Qi Guo, Zhi-Xin Ma, et al.
BMJ (Clinical Research Ed.)|March 31, 2026
Medial retropharyngeal nodal region sparing radiotherapy in nasopharyngeal carcinoma: five year analysis of open label, non-inferiority, multicentre, randomised phase 3 trialShun-Xin Wang, Ya-Lan Tao, Tian-Sheng Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2026
TQB2618 plus penpulimab, alone or in combination with chemotherapy, for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, two-cohort, phase 2 trialCheng Xu, Si-Yang Wang, Man Nie, et al.
Nature Medicine|June 6, 2023
The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatmentJiawei Lv, Yuan Wei, Jian-Hua Yin, et al.
Pageof 57

Showing results (541-550 of 565) with videos related to

Sort By:
Pageof 57
European Journal of Cancer (Oxford, England : 1990)|February 26, 2017
Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomised controlled trialLei Chen, Chao-Su Hu, Xiao-Zhong Chen, et al.
Cell Reports. Medicine|February 12, 2025
Advanced image-identified extranodal extension of retropharyngeal lymph nodes in the refinement of N classification for nasopharyngeal carcinomaWei Jiang, Gao-Yuan Wang, Guan-Jie Qin, et al.
Journal of Hematology & Oncology|October 18, 2022
Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemiaYa-Fang Ma, Ying Lu, Qian Wu, et al.
Molecular Cancer|January 12, 2021
Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responsesYu-Pei Chen, Jia-Wei Lv, Yan-Ping Mao, et al.
BMJ (Clinical Research Ed.)|February 6, 2023
Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trialYan-Ping Mao, Shun-Xin Wang, Tian-Sheng Gao, et al.
Journal of the National Cancer Institute|October 23, 2020
A Gene-Expression Predictor for Efficacy of Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal CarcinomaYuan Lei, Ying-Qin Li, Wei Jiang, et al.
Plos One|October 15, 2015
Impact of Chemotherapy Delay on Overall Survival for AML with IDH1/2 Mutations: A Study in Adult Chinese PatientsJing-Han Wang, Qi Guo, Zhi-Xin Ma, et al.
BMJ (Clinical Research Ed.)|March 31, 2026
Medial retropharyngeal nodal region sparing radiotherapy in nasopharyngeal carcinoma: five year analysis of open label, non-inferiority, multicentre, randomised phase 3 trialShun-Xin Wang, Ya-Lan Tao, Tian-Sheng Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2026
TQB2618 plus penpulimab, alone or in combination with chemotherapy, for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, two-cohort, phase 2 trialCheng Xu, Si-Yang Wang, Man Nie, et al.
Nature Medicine|June 6, 2023
The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatmentJiawei Lv, Yuan Wei, Jian-Hua Yin, et al.
Pageof 57